Dr. David S. Johnson is an inventor, entrepreneur, and expert in single-cell genomics. Dr. Johnson holds a degree in Biology from Duke University, a graduate certificate in Statistics from Penn State, and a Ph.D. in Genetics from Stanford University. For his postdoctoral work, he was the ENCODE Project Director at the Stanford Human Genome Center. There, Dr. Johnson was a respected leader in the genomics community and led a number of consortium projects. Notably, he co-invented ChIP-Seq, culminating in a frequently cited article in Science magazine and a successful $14.6 million grant from NIH/NHGRI. After Stanford, Dr. Johnson was among the founding members and COO of Natera, a Silicon Valley genetics startup funded by Sequoia Capital and other top-tier venture capitalists. At Natera, Dr. Johnson led a team of 15 and was responsible for all clinical operations, laboratory research, clinical studies, and clinical product development. As COO, Dr. Johnson was responsible for invention and commercialization of two genomic products for preimplantation genetic diagnosis (PGD), which captured >30% market share less than a year after commercial launch. Additionally, he authored two successful SBIR grants from the NIH/NICHD, for a total of up to $3.6 million in research funding. He also secured business partnerships with Illumina and Ferring Pharmaceuticals worth >$1 million. Dr. Johnson is co-inventor of the Cell-Seq™ technology and is responsible for technology development and research collaborations.